Opko Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Continuing-operations revenue increased 16% in the 3rd quarter of 2026 compared with the 3rd quarter of 2025; consolidated revenue was $65.4 million versus $56.4 million.
- Global Products generated $48.4 million in revenue, including $41.8 million of product revenue, up 11%, and $6.6 million of licensing, collaboration, and other revenue.
- Global Products operating income was $6 million, compared with an operating loss of $1.2 million in the 3rd quarter of 2025.
- Innovative Biotech generated $17 million in revenue, including Pfizer gross profit share of $8.7 million and BARDA funding of $7.5 million; its operating loss was $26.8 million.
- Consolidated operating loss was $31.4 million, compared with $33.6 million in the 3rd quarter of 2025; R&D expense was $32.2 million versus $29.8 million.
- OPKO ended the quarter with $403.2 million in cash, cash equivalents, and restricted cash, and repurchased approximately 7.2 million shares for $10.6 million at an average price of $1.48 per share.
- LabCorp agreed to acquire select BioReference assets for approximately $722 million in cash at closing, subject to an adjustment based on revenue leading up to closing; OPKO is also eligible for royalty payments of up to $150 million based on 4Kscore revenue over the next 10 years.
- OPKO received $125 million of secured notes from Healthcare Royalty Partners, secured by its Mazdutide royalty interest; the notes mature in 2044, and total payments are capped at 1.5 times the amount funded.
- BioReference is classified as a held-for-sale asset and presented as discontinued operations for all periods, with prior periods recast; the LabCorp transaction remains subject to regulatory approvals and customary closing conditions.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this event is being recorded. I would now like to turn the conference over to Vivian Cervantes, Alliance Advisors Investor Relations.
Please go ahead. Thank you, operator.
Good afternoon, everyone. Thank you for joining us in today's call to discuss OPKO Health's financial results for the third quarter of 2026. I would like to remind you that any statements made during this call by management, other than statements of historical fact, will be considered forward-looking, and as such, are subject to risks and uncertainties that could materially affect the company's results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 4, 2026. Except as required by law, OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.
Regarding the format of today's call, Dr. Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, President and Vice Chairman, will then review OPKO's pipeline and business. After that, Adam Logal, OPKO's Chief Financial Officer, will review the announced Labcorp transaction, the company's third quarter financial results, and its outlook. We will then open the line to the call for questions. I would now like to turn the call over to Dr. Frost.
Good afternoon, and thank you for joining us today. The Labcorp transaction marks a defining moment for OPKO. Once closed, it will complete our exit from clinical laboratory services, sharpen our focus, and allow our management attention, our people, and our capital to focus on biotech innovation and our global products business. Adam will provide the transaction and financial details later. This reflects the approach we have applied throughout OPKO's history: build differentiated businesses and assets, validate their value, monetize them at the right time, and redeploy capital into our highest return opportunities. Going forward, OPKO is centered on two continuing businesses. Innovative biotech brings together ModeX and OPKO Biologics with a broad portfolio across oncology, immunology, infectious disease, and endocrinology. Global products include RAYALDEE and our international pharmaceutical operations with established commercial capabilities and recurrent cash flow. The third quarter was one of steady execution across our pipeline.
ModeX expanded its clinical activity, completed enrollment in the planned phase I cohorts for MDX2301, and continue advancing our differentiated in vivo CAR T platform toward the clinic. Elias will discuss that progress. The collaborations with Merck, Regeneron, Entera Bio, and BARDA continue to add scientific capability, external validation, and non-dilutive support, while NGENLA, RAYALDEE, and our international operations contribute to the strength of the business. During the quarter, we purchased over 7 million shares of our common stock, leaving over 80 million of our 220 million authorization for additional purchases. With that, I'll turn the call over to Elias for a review of our pipeline and businesses.
Elias? Thank you, Phil, and good afternoon, everyone.
I'll begin with ModeX, where our work during the third quarter centered on clinical execution and preparation for the next stages of development. We continue to advance multiple clinical programs while building the foundation for the next wave of opportunities across our portfolio. Let me start with MDX-2001, which is our tetraspecific T-cell engager for solid tumors. MDX-2001 targets two tumor antigens, Trop-2 and c-Met, while engaging CD3 and CD28 on T-cells. The design is intended to address tumor heterogeneity while providing both T-cell activation and co-stimulation. As of September 30th, we had enrolled 41 patients in the phase I study. We continued intravenous dose escalation against diverse tumor types in order to establish a positive safety profile, and then refined our enrollment strategy to focus on tumor types where the biology and emerging clinical experience suggest the greatest potential for activity.
We have also received regulatory approval to proceed with subcu dosing, subcutaneous dosing, which may provide greater dosing flexibility, potentially improve tolerability, and make treatment more convenient for patients. These studies will begin in late 2026 or early 2027. Our priorities are to continue enrollment in selected tumor populations, further characterize the safety and pharmacologic profile, and initiate subcutaneous dosing cohorts. We're also planning to submit early clinical data at an upcoming scientific meeting. MDX-2003 is our CD19/CD20 tetraspecific T-cell engager and expander. MDX-2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells. Dual targeting on the tumor cells is designed to address antigen loss and immune escape, which is a frequent cause of relapse. While CD28 co-stimulation combined with CD3 activation is intended to support more sustained T-cell activity and hopefully greater efficacy.
Our initial focus remains B-cell malignancies with autoimmune indications as a potential follow-on opportunity. During the quarter, we continued dose escalation designed to generate safety, pharmacologic, and dose selection information. Six sites were active across Australia and Israel as of September 30th, with two more sites being added this quarter. We have also received approval to begin clinical trials of MDX-2003 in Europe, with eight additional sites being added in Spain and Italy by early 2027. We're also preparing for subcutaneous administration, which we expect to begin in 2027, subject to regulatory and ethics approval. MDX-2004 is our multispecific immune rejuvenator. MDX-2004 is designed to activate and support T cells through CD3, CD28, and 4-1BB signaling. Rather than targeting a tumor antigen, it is intended to stimulate the patient's immune stem cells to replenish T-cell function that is often exhausted by chronic stimulation.
Our vision is to make MDX-2004 applicable to a wide range of indications where enhancement of the immune response against tumors or other targets is necessary. As of September 30th, 16 patients have been enrolled, and the study has progressed into its fourth dose cohort. During the quarter, we moved to weekly dosing to improve drug exposure and received approval from relevant health authorities to begin subcutaneous dosing, which will enable easier and more convenient administrations. These studies will begin in early 2027. We also opened a clinical site in Moldova, where checkpoint inhibitors are not routinely available through the public health system, and this allows us to study MDX-2004 in PD-1 naive patients and to understand whether prior checkpoint exposure affects its activity, which will help inform whether a future combination with a PD-1 inhibitor is warranted.
Our MDX-2301 is our multispecific COVID-19 antibody developed with funding from BARDA. MDX-2301 targets conserved regions of the SARS-CoV-2 spike protein and is designed to maintain activity across evolving variants, particularly for immunocompromised individuals who may not be adequately protected by vaccination. All planned cohorts in the phase I study have been enrolled, and the blinded safety profile has been favorable across the dose levels evaluated. The final repeat dose was scheduled in September, and the team is now completing follow-up and compiling pharmacokinetic, immunogenicity, and viral neutralization data. Excuse me. We are also advancing a high-concentration formulation to support a more practical subcutaneous presentation. Together, this will inform potential phase II and phase III development in high-risk populations. BARDA also continues to support our multispecific influenza program. MDX3001 is our first in vivo CAR-T development program.
Our in vivo CAR-T platform combines targeted lipid nanoparticles with ModeX multispecific antibodies to deliver a CAR payload directly to several selected cell types in the body. We believe this approach offers important advantages over ex vivo CAR-T, including off-the-shelf administration, the potential for redosing, and more efficient targeting. Preclinical studies have demonstrated in vivo CAR-T cell generation and B-cell depletion in blood and lymphoid tissues in humanized mouse as well as non-human primate models. We continue to target first-in-human studies in mid-2027, initially in autoimmune disease. This shift from our previously announced timeline reflects new regulatory requirements for initiating investigator-initiated clinical trials in China. Moving to our partnerships. Our collaboration with Merck on the Epstein-Barr virus vaccine continues to progress. The phase I analysis is intended to support adjuvant selection and inform the design of a potential phase II study, with timing and design subject to Merck's decisions.
Our Regeneron collaboration remains focused on four initial discovery programs, combining Regeneron's antibody binders with the ModeX multispecific platform, and all four programs have advanced per plan. Next, let me switch and talk about our OPKO Biologics and global products, which continue to also make meaningful progress. Outside of ModeX programs, the phase I/IIa study of OPK-88006, which is our once weekly GLP-1 glucagon receptor agonist, continues in healthy volunteers. We are currently screening participants with presumed MASH for a planned 20-week portion of the study. We are also advancing our long-acting growth hormone antagonist for acromegaly and our oral PTH program with Entera Bio for hypoparathyroidism. NGENLA continues to expand globally through Pfizer, supported by ongoing label expansion studies. Within our global product segments, RAYALDEE and our international pharmaceutical operations continue to deliver recurring revenue and cash flow that help fund our innovation. Now finally, BioReference Health. First, let me just recognize the BioReference team.
Over the past two years, as you know, they restructured the business around its core New York and New Jersey operations, correctional health, and the 4Kscore test, significantly improving its operating efficiency. That work helped position the business for the transaction with Labcorp. Until closing of the transaction, which remains subject to regulatory approvals and customary closing conditions, BioReference will continue operating and serving patients, physicians, and clients, and we will work very closely with Labcorp to support a smooth transition following closing. Further details will be provided by Adam Logal about this transaction. In closing, this is really a transformational period for OPKO. Once closed, the Labcorp transaction will complete our transition to a focused biopharmaceutical company, as mentioned by Phil, and our pipeline continues to advance on multiple fronts.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
